<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01488188</url>
  </required_header>
  <id_info>
    <org_study_id>FM-01 V1</org_study_id>
    <nct_id>NCT01488188</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual Route</brief_title>
  <official_title>A Controlled Study to Determine the Immunogenicity and Safety of Cold-adaptive Live Attenuated Influenza Vaccine (Flumist) Administered by the Nasal and Sublingual Route in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Vaccine Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Vaccine Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: It is well established that live attenuated organisms can be highly effective
      vaccines, immune responses elicited can often be of greater magnitude and of longer duration
      than those produced by non-living antigens and are often able to confer protection after a
      single dose. Unlike killed influenza vaccine preparations injected by the parenteral route,
      live influenza vaccines are able to induce potent secretory (mainly IgA) antibody responses
      in the airway mucosae and can also evoke cell mediated responses. T cell proliferation,
      cytokine production, cytotoxic T cell responses and antibody-dependent cell cytotoxicity have
      all been elicited by live attenuated vaccines.

      There has been a history of the use of live attenuated flu vaccines as safe and effective
      vaccines for the prevention of flu in animals and humans. Live-attenuated cold-adapted
      influenza vaccines have been proved to be highly efficacious to protect against clinical fly
      symptoms. Among these, FluMist, a nasal vaccine formulation developed by Medimmune Inc, has
      been approved by the US FDA. Recent side by side clinical trials have demonstrated that this
      nasal vaccine was significantly superior to conventional killed flu vaccine in protecting
      against flu symptoms.

      Sublingual administration of live influenza virus at a dose lethal by the nasal route was
      well tolerated and did not redirect virus to the olfactory bulb. In addition, in a recent
      Phase I clinical study (NCT00820144) conducted in France, the sublingual administration of
      recombinant cholera toxin B subunit (rCTB,up to 1 mg) in healthy adult volunteers was found
      to be safe.

      A major issue has arisen regarding the ease with which vaccines could be administered to
      young children, especially infants, and to elderly subjects in whom nasal vaccination has not
      been possible and/or approved due to difficulties of administering nasal vaccines in infants
      and to undesired side effects related to frequent rhinitis and sneezing episodes in elderly
      subjects. This study is designed to investigate the safety, tolerability and immunogenicity
      of a new route of administration of vaccines, using the nasal FluMist formulation as
      prototype vaccine.

      Objectives: To evaluate the immunogenicity and safety of a nasal and sublingual influenza
      virus vaccine (FluMist) in healthy adult volunteers

      Study design: This will be a randomized study on a total 40 subjects; each 20 subjects will
      receive vaccine via nasal and sublingual route, respectively
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Passive Haemagglutination Inhibition Titer.</measure>
    <time_frame>21 days after vaccination</time_frame>
    <description>Passive haemagglutination inhibition titer of serum at 21 days after vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Immunoglobulin G (IgG) and Immunoglobulin A (IgA)-Antibody Secreting Cell Number to Flu Virus</measure>
    <time_frame>7 days after vaccination</time_frame>
    <description>Flu virus-specific IgG- and IgA -antibody secreting cells per ml of blood at 7 days after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salivary IgA</measure>
    <time_frame>21 days after vaccination</time_frame>
    <description>Salivary Flu-specific IgA titer at Days 21 after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell Mediated Immune Responses</measure>
    <time_frame>21 days after vaccination</time_frame>
    <description>Interferon gamma production in peripheral blood monocyte (PBMC) after in vitro re-stimulation with influenza virus antigen at 21 days after vaccination.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Influenza vaccine-Nasal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nasal administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza vaccine -Sublingual</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sublingual administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccine</intervention_name>
    <description>Administration of 1 dose (0.2 ml) by nasal route</description>
    <arm_group_label>Influenza vaccine-Nasal</arm_group_label>
    <other_name>Flumist (2011-2012)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccine</intervention_name>
    <description>Administration of 1 dose (0.2 ml) by sublingual route</description>
    <arm_group_label>Influenza vaccine -Sublingual</arm_group_label>
    <other_name>Flumist (2011-2012)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers who are able and willing to give informed consent, following a
             detailed explanation of participation in the study.

          -  Volunteers who will be available for the duration of the study and available for
             scheduled and potential additional visits

        Exclusion Criteria:

          -  Subjects with any clinically significant medical or psychiatric condition or
             clinically significant abnormal serum biochemistry or haematology results that, in
             opinion of the Investigator, preclude participation in the study.

          -  Female subjects who are pregnant (using urine test) or breast-feeding, or of
             childbearing potential and unwilling to use a reliable method of contraception (e.g.
             oral contraceptives or contraceptive during sexual activities such as a condom,
             contraceptive diaphragm, intrauterine device, hormonal contraceptive, or intercourse
             with a male partner who has had a vasectomy etc.) throughout the study period.

          -  Subjects who have known airway hypersensitivity to one of Flu vaccine excipients
             within 14 days prior to administration of study medication.

          -  Subjects who have known buccal hypersensitivity to any component of the vaccine or
             buffer solution used in this study, including subjects with phenylketonuria.

          -  Subjects with direct contact with at risk groups (e.g. patients in special care units,
             immuno-compromised individuals, pregnant women, children under 2 years of age and
             individuals over 70 years).

          -  Subjects with a known impairment of immune function including seropositive for HIV or
             those receiving (or have received in the 6 months prior to study entry) cytotoxic
             drugs immunosuppressive therapy (including systemic corticosteroids).

          -  Subjects with a significant acute febrile illness (fever of 38.0 Celsius degree or
             more) at time of dosing.

          -  Subjects who have chronic diseases: Chronic diseases will include all autoimmune and
             immuno-compromising conditions and any other chronic condition, which at the judgement
             of the Investigator, may put the subject at higher risk of side effects from the study
             vaccine. Conditions in the latter category might include unexplained anaemia,
             hepato-biliary disease, uncontrolled hypertension, subjects with prosthetic joints or
             heart valves, etc.

          -  Subjects with a current problem, based on history, with substance abuse or with a
             history of substance abuse

          -  Subjects who are currently involved in a clinical trial, have taken an investigational
             drug or have received investigational or licensed vaccines in the preceding 4 weeks or
             anticipate receiving a vaccine other than study medication during the first 4 weeks of
             the study

          -  Subjects who have known hypersensitivity to eggs or egg proteins

          -  Subjects who have chronic respiratory infections or syndromes

          -  Unable to receive oral (sublingual) administration.

          -  Receiving anti-viral agents.

          -  Subjected to contraindications and/or precautions described in drug information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cecil Czerkinsky, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Vaccine Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2011</study_first_submitted>
  <study_first_submitted_qc>December 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2011</study_first_posted>
  <results_first_submitted>July 31, 2013</results_first_submitted>
  <results_first_submitted_qc>November 5, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 23, 2013</results_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza vaccine</keyword>
  <keyword>nasal route</keyword>
  <keyword>sublingual route</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruit volunteers at Clinical Trial Center in Seoul National University Hospital</recruitment_details>
      <pre_assignment_details>Randomly group assignment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Influenza Vaccine -Sublingual</title>
          <description>Sublingual administration
Influenza vaccine : Administration of 1 dose (0.2 ml) by sublingual route</description>
        </group>
        <group group_id="P2">
          <title>Influenza Vaccine-Nasal</title>
          <description>Nasal administration
Influenza vaccine : Administration of 1 dose (0.2 ml) by nasal route</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Influenza Vaccine -Sublingual</title>
          <description>Sublingual administration
Influenza vaccine : Administration of 1 dose (0.2 ml) by sublingual route</description>
        </group>
        <group group_id="B2">
          <title>Influenza Vaccine-Nasal</title>
          <description>Nasal administration
Influenza vaccine : Administration of 1 dose (0.2 ml) by nasal route</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.5" spread="5.8"/>
                    <measurement group_id="B2" value="25.9" spread="4.5"/>
                    <measurement group_id="B3" value="25.7" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Passive Haemagglutination Inhibition Titer.</title>
        <description>Passive haemagglutination inhibition titer of serum at 21 days after vaccination.</description>
        <time_frame>21 days after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine -Sublingual</title>
            <description>Sublingual administration
Influenza vaccine : Administration of 1 dose (0.2 ml) by sublingual route</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine-Nasal</title>
            <description>Nasal administration
Influenza vaccine : Administration of 1 dose (0.2 ml) by nasal route</description>
          </group>
        </group_list>
        <measure>
          <title>Passive Haemagglutination Inhibition Titer.</title>
          <description>Passive haemagglutination inhibition titer of serum at 21 days after vaccination.</description>
          <units>Titer</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380" lower_limit="5" upper_limit="560"/>
                    <measurement group_id="O2" value="440" lower_limit="10" upper_limit="1120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Immunoglobulin G (IgG) and Immunoglobulin A (IgA)-Antibody Secreting Cell Number to Flu Virus</title>
        <description>Flu virus-specific IgG- and IgA -antibody secreting cells per ml of blood at 7 days after vaccination</description>
        <time_frame>7 days after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine -Sublingual</title>
            <description>Sublingual administration
Influenza vaccine : Administration of 1 dose (0.2 ml) by sublingual route</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine-Nasal</title>
            <description>Nasal administration
Influenza vaccine : Administration of 1 dose (0.2 ml) by nasal route</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Immunoglobulin G (IgG) and Immunoglobulin A (IgA)-Antibody Secreting Cell Number to Flu Virus</title>
          <description>Flu virus-specific IgG- and IgA -antibody secreting cells per ml of blood at 7 days after vaccination</description>
          <units>cells/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.85" lower_limit="0.0" upper_limit="120.0"/>
                    <measurement group_id="O2" value="15.0" lower_limit="0.0" upper_limit="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Salivary IgA</title>
        <description>Salivary Flu-specific IgA titer at Days 21 after vaccination</description>
        <time_frame>21 days after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine -Sublingual</title>
            <description>Sublingual administration
Influenza vaccine : Administration of 1 dose (0.2 ml) by sublingual route</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine-Nasal</title>
            <description>Nasal administration
Influenza vaccine : Administration of 1 dose (0.2 ml) by nasal route</description>
          </group>
        </group_list>
        <measure>
          <title>Salivary IgA</title>
          <description>Salivary Flu-specific IgA titer at Days 21 after vaccination</description>
          <units>Titer</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3550" lower_limit="1040" upper_limit="28800"/>
                    <measurement group_id="O2" value="3600" lower_limit="480" upper_limit="27200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cell Mediated Immune Responses</title>
        <description>Interferon gamma production in peripheral blood monocyte (PBMC) after in vitro re-stimulation with influenza virus antigen at 21 days after vaccination.</description>
        <time_frame>21 days after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine -Sublingual</title>
            <description>Sublingual administration
Influenza vaccine : Administration of 1 dose (0.2 ml) by sublingual route</description>
          </group>
          <group group_id="O2">
            <title>Influenza Vaccine-Nasal</title>
            <description>Nasal administration
Influenza vaccine : Administration of 1 dose (0.2 ml) by nasal route</description>
          </group>
        </group_list>
        <measure>
          <title>Cell Mediated Immune Responses</title>
          <description>Interferon gamma production in peripheral blood monocyte (PBMC) after in vitro re-stimulation with influenza virus antigen at 21 days after vaccination.</description>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1666" lower_limit="92" upper_limit="38599"/>
                    <measurement group_id="O2" value="1743" lower_limit="4" upper_limit="11674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Influenza Vaccine -Sublingual</title>
          <description>Sublingual administration
Influenza vaccine : Administration of 1 dose (0.2 ml) by sublingual route</description>
        </group>
        <group group_id="E2">
          <title>Influenza Vaccine-Nasal</title>
          <description>Nasal administration
Influenza vaccine : Administration of 1 dose (0.2 ml) by nasal route</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>standard terminology</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Mild fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pruitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jae Seung Yang</name_or_title>
      <organization>International Vaccine Institute</organization>
      <phone>82-2-881-1198</phone>
      <email>jsyang@ivi.int</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

